Results from the world’s largest prospective artificial intelligence study revealed the system could significantly benefit breast cancer screening programs.
The new atrial shunt from Alleviant Medical was designed to treat heart failure without leaving a permanent implant behind. The FDA granted the technology its breakthrough device designation and approved additional research.
Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.
In some cases, certain classes of anti-amyloid beta (Aβ) drugs resulted in individuals’ brain volume decreasing more rapidly while using the drug than they would have if they had not received treatment at all.
The study’s primary endpoint, amputation-free survival after six months, was seen in 66.1% of CLTI patients who underwent transcatheter arterialization.
Weekend warriors who take brisk walks of around four miles just once or twice per week enjoy lower cardiovascular and all-cause mortality than their sedentary peers.